Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Off-treatment survival after discontinuation of the anti-PD1 therapy with Nivolumab or Pembrolizumab monotherapy or Nivolumab + Ipilimumab combination therapy in patients with advanced Melanoma

Trial Profile

Off-treatment survival after discontinuation of the anti-PD1 therapy with Nivolumab or Pembrolizumab monotherapy or Nivolumab + Ipilimumab combination therapy in patients with advanced Melanoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jun 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Jun 2018 New trial record
    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top